First Artificial Human Platelet Lysate BioScience Raises the Bar in Cell Culture Technology with artificial HPL PL BioScience develops worldwide first artificial Human Platelet Lysate (HPL) solution, and thus a key ingredient for the research & production of cell-based pharmaceuticals. In partnership with the Korean biotech DewCell
We are thrilled to unveil our latest innovation: ELAREM™ Ultimate-FD PLUS The gamma irradiated Human Platelet Lysate ELAREM™ Ultimate-FD PLUS is designed to meet the needs of cell manufacturing applications requiring proven viral reduction. As a xeno-free cell culture supplement, ELAREM™ Ultimate-FD PLUS supports the safe and
We are thrilled to announce a significant milestone for PL BioScience! In a recent press release, we reveal that we have successfully closed a €7.8 million Series A financing round. This Series A funding marks a pivotal moment in our company’s growth journey. This substantial infusion
New Press Release: Sustainable Cell Culture Medium A new press release "Recently at the bench: cell culture with Human Platelet Lysate - Sustainable Cell Culture Media" in the German Laborjournal edition from December 2021 was published. Our CEO Hatim Hemeda had the opportunity to write a guest
PL BioScience starts up complementary workspace at Medace The Aachen-based biotechnology company PL BioScience was founded in 2015 as a spin-off of the RWTH Aachen University, with the idea of delivering animal component-free cell culture supplements. PL BioScience has developed an advanced nutrient solution for
Vero cells are used in the development of Covid-19 vaccines Vero cells are used a lot in research and industry. Time to have a closer look at this cell line: Vero cells are continuous cell lines that was derived from the kidney of an African green monkey
A new publication from Kouroupis et al. published in CYTOTHERAPY in July 2020 found out that infrapatellar fat pad (IFP)-mesenchymal stem cells (MSCs) manufactured with human Platelet Lysate (hPL) show enhanced immunomodulatory properties. Findings have potential for a minimally invasive cell therapy for joint disease The authors even
Human Platelet Lysate should seriously considered as the new standard "hPL has favorable properties in terms of ethics and scientific practice and should seriously be considered as a new standard cell culture medium substitute". HPL can replace FCS as a protein source This is only one of the
